A 96-well surrogate survival assay coupled with a special short interfering RNA vector for assessing cancer gene targets with enhanced signal/noise ratio and its utility in HTS for cancer therapeutic targets

Assay and Drug Development Technologies

Volumn 3, Issue 4, 2005, Pages 401-412

  Yu, De Hua ^a   Chatterton, Jon E ^a   Bliesath, Joshua R ^a   Sundaram, Roshni ^a   Ke, Ning ^a   Nguy, Vivian ^a   Meyhack, Bernd ^b   Wong Staal, Flossie ^a   Li, Qi Xiang ^a  

^a Immusol Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; LUCIFERASE; SMALL INTERFERING RNA;

AGAR MEDIUM; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CELL SURVIVAL; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG DETERMINATION; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; GENE CASSETTE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GROWTH INHIBITION; HELA CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PHENOTYPE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA VECTOR; SIGNAL NOISE RATIO; VALIDATION PROCESS; WESTERN BLOTTING;

BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; GENETIC VECTORS; HELA CELLS; HUMANS; INDICATORS AND REAGENTS; LUCIFERASES; MOLECULAR SEQUENCE DATA; OXAZINES; PROTO-ONCOGENES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; XANTHENES;

EID: 27144451447     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2005.3.401     Document Type: Article

References (13)

1. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 2001;411:355-365.
2. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
3. Vassilev LT, Kazmer S, Marks IM, Pezzoni G, Sala F, Mischke SG, Foley L, Berthel SJ: Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and cancer cells: Identification of two novel cell-cycle inhibitors. Anticancer Drug Des 2001;16:7-17.
4. Ke N, Albers A, Claassen G, Yu DH, Chatterton JE, Hu X, Meyhack B, Wong-Staal F, Li QX: One-week 96-well soft agar growth assay for cancer target validation. Biotechniques 2004;36:826-833.
5. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, Rossi J: Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002;20:500-505.
6. Li QX, Robbins JM, Welch PJ, Wong-Staal F, Barber JR: A novel functional genomics approach identifies mTERT as a suppressor of fibroblast transformation. Nucleic Acids Res 2000;28:2605-2612.
7. Shin SI, Freedman VH, Risser R, Pollack R: Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci U S A 1975;72:4435-4439.
8. Zheng L, Liu J, Batalov S, Zhou D, Orth A, Ding S, Schultz PG: An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci U S A 2004;101:135-140.
9. Tran N, Cairns MJ, Dawes IW, Arndt GM: Expressing functional siRNAs in mammalian cells using convergent transcription. BMC Biotechnol 2003;3:21.
10. Liu X, Erikson RL: Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 2003;100:5789-5794.
11. Bjornsti MA, Houghton PJ: The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004;4:335-348.
12. Neckers L, Ivy SP: Heat shock protein 90. Curr Opin Oncol 2003;15:419-424.
13. Ranger AM, Malynn BA, Korsmeyer SJ: Mouse models of cell death. Nat Genet 2004;28:113-118.